A Prematurely Halted, Randomized, Controlled Clinical Trial of Alendronate Treatment in Patients with Gaucher Disease
Publisher
Springer Singapore
Reference9 articles.
1. Barton, N. W., Brady, R. O., Dambrosia, J. M., et al. (1991). Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher’s disease. The New England Journal of Medicine, 324, 1464–1470. 2. Beutler, E., & Grabowski, G. (2001). Gaucher disease. In C. R. Scriver, A. L. Beaudet, D. Valle, et al. (Eds.), The metabolic and molecular basis of inherited disease (8th ed., pp. 3635–3638) New York, NY: McGraw-Hill. 3. Ciana, G., Cuttini, M., & Bembi, B. (1997). Short-term effects of pamidronate in patients with Gaucher’s disease and severe skeletal involvement [letter]. The New England Journal of Medicine, 337, 712. 4. Elstein, D., Hadas-Halpern, I., Itzchaki, M., Lahad, A., Abrahamov, A., Zimran, A. (1996). Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells, Molecules and Diseases, 22, 101–108. 5. Harinck, H. I., Bijvoet, O. L., van der Meer, J. W., Jones, B., & Onvlee, G. J. (1984). Regression of bone lesions in Gaucher’s disease during treatment with aminohydroxypropylidene bisphosphonate [letter]. Lancet, 2, 513.
|
|